WITH BIOCOPY IDENTIFY AND VALIDATE VACCINE CANDIDATES – EFFICIENTLY AND RAPIDLY
The complexity and mutagenicity of viral and bacterial pathogens requires a new flexibility and efficiency in the development of vaccines. BioCopy’s technology helps select vaccine candidates very soon after pathogen identification. In this way, vaccines against new pathogens can be developed much faster and more efficiently.
With our cutting-edge high-throughput microarray technology, we can handle the vast complexity of mutated pathogen variants and translate it into processable data for vaccine development. We map the complexity of pathogens by synthesizing immunogens on a chip and detect the immune response using serum samples directly on the chip.
The BioCopy microfluidics platform with parallel detection of thousands of samples allows for rapid turnover and saves serum specimen. This significantly shortens development time to support early market availability of urgently needed vaccines.
BioCopy’s technology can be applied to influenza or SARS-CoV-2 – prominent examples of high mutation rates leading to escape mutants that can bypass vaccine protection.
BioCopy technology in the field of B-cell response
First, thousands of proteins are produced in parallel from DNA with Biocopy’s high-throughput technology. A subset of the copied proteins can represent targets of pathogens like viruses and can be used for the development of novel vaccines.
Second, blood sera with antibodies from recovered individuals are flushed over the microarray with the copied proteins. Pathogen epitopes bound by these antibodies are potential candidates for a vaccine as they can stimulate the immune system of a naïve person (not yet exposed to the pathogen).
We're your partner
With our proprietary technology, we screen thousands of pathogen fragments for interactions with serum antibodies in parallel, on a single chip. In this way, we can identify vaccine candidates and provide early indications of the efficacy of existing vaccines as well as new vaccines in development.
Manufacturers of vaccines gain a holistic view of the immune response and a comprehensive insight into the molecular mechanism of their vaccine candidates. This can significantly accelerate development.
References
Swiss Institute of Virology and Immunology
In 2021, BioCopy and the Swiss Institute of Virology and Immunology (IVI) initiated a collaboration for vaccine development against African Swine Fever Virus (ASFV). | |
In 2020, BioCopy characterized antibodies for adapted COVID treatment of alpha mutants.
|
With its rapid, high throughput identification and characterization of vaccines, BioCopy can achieve a major time advantage. Time that can be worth millions: millions of human lives in the event of a pandemic – millions in sales and a unique market position due to a head start in market approval. |
Pascal BrenneisenMember of the Board of Directors of BioCopy AG |